GuidelineZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].
Guideline in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Matching-adjusted indirect comparison between asciminib and flumatinib as first-line treatment for chronic myeloid leukemia in China.Translational cancer research · 2026Article
- [Efficacy and Long-term Prognosis of Flumatinib in the Treatment of Chronic Myelocytic Leukemia].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- [Inter-laboratory comparison of international standardized BCR::ABL1 (P210) mRNA of chronic myeloid leukemia patients by digital PCR].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience.Mediterranean journal of hematology and infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The guideline for the diagnosis and treatment of chronic myeloid leukemia (CML) in China (2025 edition) has been revised based on its 2020 version, incorporating advances in the field of CML diagnosis and treatment over the past 5 years. With reference to the revised 2022 International Consensus Criteria, the threshold for lymphoblasts in lymphoid blast transformation is clearly defined. The EUTOS Long-Term Survival score is recommended to evaluate the patient's risk status at diagnosis. Meanwhile, a prediction model for tyrosine kinase inhibitor (TKI) treatment failure derived from Chinese multicenter data is also recommended. The prognostic significance of cytogenetic and molecular abnormalities should be considered. Newly therapeutic drugs include asciminib, olverembatinib, and ponatinib. This version of the guideline systematically elaborates on the decision-making principles for first-line and later-line medications. Milestone responses are of guiding significance for treatment strategy adjustments; however, we emphasize that molecular milestone responses should be interpreted individually. Concurrently, it proposes TKI dose optimization based on efficacy and safety. The implementation criteria for treatment-free remission, postdiscontinuation monitoring, and fertility-related issues have been adjusted to minimize toxicities and improve quality of life while ensuring efficacy. Allogeneic hematopoietic stem cell transplantation remains valuable for patients with multidrug TKI resistance or intolerance and those in advanced phases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.